Ibrutinib inhibits the replication of multiple poxviruses by targeting the Bruton tyrosine kinase

ABSTRACT The recent surge in global monkeypox (mpox) outbreaks highlights the critical need for developing antiviral agents targeting orthopoxvirus infections. Ibrutinib, a selective Bruton tyrosine kinase (BTK) inhibitor initially approved by the FDA in 2013 for treating chronic lymphocytic leukemi...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Kang Niu, Xiru Wang, Qiwei Jiang, Kai Liu, Shijie Xie, Baifen Song, Wenxue Wu, Xiao Li, Chen Peng
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology 2025-09-01
coleção:	Journal of Virology
Assuntos:	Ibrutinib BTK mpox virus lumpy skin disease virus antiviral action
Acesso em linha:	https://journals.asm.org/doi/10.1128/jvi.00517-25
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!